版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
leukemia1LeukemiaDefinition:Agroupofmalignantclonalmalignantdiseaseofhematopoietictissue.Blockageofcelldifferentationindifferentstages.Accumulationofleukemiccellsinbonemarrow orotherorgans.Impairedproductionofnormalbloodcells.2ProgenitorcellStemcell3Normobalst原红Basophilicnormoblast早幼红Polychromaticnormoblast中幼红Ortho-chromaticnormoblast晚幼红4Myeloblast原粒Promyelocyte早幼粒Myelocyte中幼粒Metamyelocyte晚幼粒bandcell杆状核Segmentedcell分叶核5Monoblast原单Promonocyte幼单核Monocyte单核6Lymphoblast原淋Prolymphocyte幼淋Lymphocyte成熟淋Lymphocyte成熟淋7Megakaryoblast原巨核Promegakaryocyte幼巨核Granularmegakaryocyte颗粒巨核Platelate-formingmegakaryocyte产板巨核89CategoryofLeukemia
AcuteLymphoblasticLeukemia(ALL)AcuteLeukemia AcuteMyeloidLeukemia(AML) ChronicMyeloidLeukemia(CML)ChronicLeukemia ChronicLymphocyticLeukemia(CLL)10Acutemyelogenousleukemia(AML)Acutemyelogenousleukemia(AML)isaclonalmalignantdiseaseofhematopoietictissuesthatischaracterizedbyaccumulationofabnormalleukemicblastcells,principallyinthemarrowandimpairedproductionofnormalbloodcells.Thus,theleukemiccellinfiltrationinmarrowisaccompanied,nearlyinvariably,byanemiaandthrombocytopenia.Theabsoluteneutrophilcountmaybelowornormal,dependingonthetotalwhitecellcount.11IncidenceofAMLIncidenceRatesbyRaceRace/EthnicityMaleFemaleAllRaces4.3per100,000men3.0per100,000womenWhite4.5per100,000men3.1per100,000womenBlack3.5per100,000men2.8per100,000womenAsian/PacificIslander3.5per100,000men2.8per100,000womenAmericanIndian/AlaskaNativea2.5per100,000men3.1per100,000womenHispanicb3.5per100,000men2.7per100,000womenAgeadjustedincidence3.6per100,000.
Medianageatdiagnosis:66years.
LifetimeriskofadiagnosisofAML:0.39%ofpeoplebornnow.
NationalCancerInstitute.SEERStatSheets:AcuteMyeloidLeukemia.
/statfacts/html/amyl.html12AgedistributionofAML13AgedistributionofALL14IncidenceofLeukemiaInChina:AcuteLeukemia>ChronicLeukemiaAdult:AML>ALLChildren:ALL>AML15EtiologyofLeukemiaVirus:HTLV-I,HTLV-II,EBIonizingRadiation:AtomicbombexposureChemicalAgents:Benzene;cytotoxicdrugschloramphenicol(氯霉素);phenylbutazone(保泰松).HereditaryFactors:Downsyndrome,21trisomy(三体)16ACUTE LEUKEMIA17FABclassificationofALLL1:smalllymphoblastictypeL2:largelymphoblastictypeL3:largelymphoblastictypewithprominentcytoplasmicvacuolization18
AcuteLymphocyticleukemia(L1)
Theblastcellshaveahighnucleocytoplasmicratio,lackvisiblenucleoliandarerelativesmall.19AcuteLymphocyticLeukemia(L2)
Theblastcellsaremainlylargeandhaveoneortwoprominentnucleoli,whichrangeinsizefromsmalltolarge.20AcuteLymphocyticLeukemia
(L3)
Theblastcellshaveprominentcytoplasmicbasophiliaandareheavilyvacuolated
21FABclassificationofAMLM0:AcuteMyelocyticleukemiawithminimallydifferentiationM1:AcuteMyeloblasticLeukemia(withoutmaturation)M2:AcuteMyeloblasticLeukemia(withmaturation,M2a,M2b)M3:AcutePromyelocyticLeukemia(M3a,M3b)M4:AcuteMyelomonocyticLeukemia(M4a,M4b,M4c,M4EO)M5:AcuteMonocyticLeukemia(M5a,M5b)M6:AcuteErythroleukemiaM7:AcuteMegakaryoblasticLeukemia22FABM0type.BlastcellswithnoevidentfeaturesofdifferentiationandwithnegativereactionsforSudanblackBandmyeloperoxidase.Onimmunophenotypicanalysis,allBandTmarkerswerenegativebuttherewasexpressionofCD13,CD33.andCD34.FABM1type.BlastcellsaresmalltomediuminsizewithahighnucleocytoplasmicratioandoneofthemcontainsanAuerrod.SudanblackBandperoxidasereactionswerepositive.Peripheralbloodfilm.Auerrod23FABM2type.ThereisdifferentiationtopromyelocytesandthereisoneneutrophilandablastcellcontaininganAuerrod.Bonemarrowfilm.FABM3type.Blastcellsareinaminority,thedominantcellbeingahypergranularpromyelocytes,somewithbundlesofAuerrods.BonemarrowfilmAuerrods24FABM4category.Therearesomeblastsshowinggranulocyticdifferentiationandothersshowingmonocyticdifferentiation.Granulocyticdifferentiationismoreobviousinthebonemarrow(left)andmonocyticintheperipheralblood(right).Bonemarrowandperipheralfilm.FABM4category,witheosinophilicdifferentiation.ThiscategoryofAMLisoftenreferredtoasM4EOAML.Therearematureeosinophilsandeosinophilprecursors.Thelatterhavelargepro-eosinophilicgranules,whichhavebasophilicstainingcharacteristics.Bonemarrowfilm.leftright25FABM5acategory.Theblastsarelargewithabundantcytoplasm.Theyshowlittlesignsofdifferentiation,butonecellhasanindentednucleus.Nucleoliarelargeandprominent.Sometimestherearefineazurophilic(嗜苯胺蓝颗粒)granules.Bonemarrowfilm.FABM5bcategory.Monocyticdifferentiationisapparent.Bonemarrowfilm.26FABM6showingerythropoiesisthatisdysplasticandgrosslymegaloblastic(巨幼红细胞);thereisanexcessofproerythroblastsbutalsoofimmaturegranulocytes,includingblastcells.Bonemarrowfilm.FABM7category.Bonemarrowtrephinebiopsyshowsblastcells(left)andincreasedreticulindeposition(right).2728FlowchartshowinghowtheWHOhierarchicalclassificationisapplied.29AML的WHO分型
伴有再现性遗传学异常的AML伴有t(8;21)(q22;q22)(AML1/ETO)的AML伴有inv(16)(p13q22)或t(16;16)(p13;q22)(CBF/MYH11)和异常骨髓嗜酸细胞的AML伴有t(15;17)(q22;q12)(PML/RAR)的APL伴有11q23(MLL)异常的AML伴有多系病态造血的AML由MDS或MDS/MPD发展而来的AML无先前的MDS或MDS/MPD病史但二系或三系病态造血细胞50%治疗相关性AML和MDSt-AML和t-MDS烷化剂或放疗所致的AML/MDSDNA柘扑异构酶抑制剂所致的AML/MDS一些可能为ALL无法按上述分型的白血病NOC-AML急性微分化白血病急性未分化白血病急性部分分化的白血病急性粒单细胞白血病急性单核细胞白血病急性红血病急性红白血病和纯红血病急性巨核细胞白血病急性嗜碱细胞白血病急性全髓细胞增生伴骨髓纤维化髓系肉瘤305-year12%5-year40%5-year61%31ClinicalFeatures
Anemia----pallor,weaknessFever----mainlyduetoinfection(G-bacilli)
Bleeding----skin,nasal,gum,intracranial(颅内)Infiltration----organsandtissues32CausesofAnemiaDecreasedproductionoferythrocytesShortenedredbloodcellsurvivaltimeHemorrahagePost-chemotherapy33CausesofinfectionReducednormalgranulocytesinnumberImpairedfunctionofgranulocytesWeakenedcellularimmunityPost-chemotherapyeffects34CausesofBleedingQuantityandqualityofplateletPerivascularinfiltrationofleukemiccellsCoagulationabnormalities(凝血异常)DIC:releaseoftissuefactor-likeprocoagulants(促凝物质)fromgranuleswithintheleukemiccells35Leukemiainfiltration
Lymphadenopathy,Hepatomegaly,Splenomegaly:especiallyinALLBone(sternumtenderness,胸骨压痛)andJointChloroma(绿色瘤):AMLOralCavityandSkin:guminfiltrationfrequentlyseeninM4,M5CentralNerveSystemLeukemia(CNS-L):mainlyinALLTesticular(睾丸)Leukemia:mainlyinALL36guminfiltrationskinbleedingandinfiltration37LabFindings:PeripheralBlood
WBC-----5.0to50.0x109/L<1.0x109/Lor>100x109/LLeukemiccellsoftencanbeseenAleukemictype:WBCdecreasedwithoutleukemiccellsAnemia-----RBCcountandHbdecreasePlateletCount-----decreased38
AcuteLeukemia----PeripheralBlood
39LabFindings:PeripheralBlood
SubtypeaccordingtoperipheralbloodLeukemictype:
WBCincreasedwithleukemiccellsSubleukemictype:
WBCnormalrangewithleukemiccellsAleukemictype:
WBCdecreasedwithoutleukemiccells40LabFindings:BoneMarrow
GeneralAspects:HyperplasiaLeukemiccellsexcessivelyproliferationInhibitingothercelllinesLeukemiccells>20%41BoneMarrow
Acuteleukemia Normal42BonemarrowAML43BonemarrowofAPL44Renjihospital
ClinicalandmolecularcharacteristicsofAPL
45Bonemarrowofacutemonocyticleukemia46BonemarrowofALL47CytochemistryofleukemiccellsALLAMLAMoLPOX-+++-~+PAS+clumporgranular-/+diffused-/+diffusedNSENAP-↑-/+NotinhibitbyNaF↓/-++InhibitedbyNaFN/↑48
CytochemicalstainPOX
NSEPAS49POXofAPLSEofAPL50ImmunologicMarkers
LineageAntigen
B-cellCD19,CD20,CD21,CD22,HLA-DRT-cellCD1,CD2,CD3,CD4,CD5,CD7,CD8MyeloidCD13,CD14,CD15,CD33,CD4151ImmunologicMarkers
M1M2M3M4M5M6M7CD13+++++--CD33+++++--CD14-±-++--CD41------+52ImmunologicMarkers
LineageAntigenErythroidGlycophorinAMegakaryocyticCD41,CD42b,CD6153CytogeneticsandMolecularBiologyAMLM3t(15;17)(q22;q21)PML/RARRAR/PMLM4EOivn(16)(q22)CBFB/MYH11M2t(8;21)(q22;q22)AML1/ETOM5t/del(11)(q23)MLL/ENL
54PMLRARaPML-RARaRARa-PML15171517
CytogeneticsandMolecularBiologyofAPL55RISKSTATUSBASEDONCYTOGENETICSANDMOLECULARMUTATIONS56Distributionofcommoncytogeneticabnormalitiesinpatientsagedlessthanormorethan60.
57TheDFSandOSofcytogeneticchangesinAMLBetter-riskIntermediate-riskPoor-riskBetter-risk1Intermediate-riskPoor-risk58CytogeneticsandMolecularBiologyALLt(9;22)(q34;q11)BCR/ABLALL-L2t(1;19);t(4;11)ALL-L3t(8;14)(q24;q32)MYC/IgH
59RenatoBassanetal,2004,OncologyHematology60MICMCategoryM----morphologyI----immunologyC----cytogeneticsM----molecularbiology61LabFindings:Others
Hyperuricemia(高尿酸血症)----tumorcelllysisLactateDehydrogenase(LDH)increaseActivityoflysozyme(溶菌酶)increase, commoninM4orM5DIC:morecommoninAMLthanALL,especiallyinM3(APL)62LabfindingsCellularmorphologyBloodroutinebiochemistryimmunologyGenemutations:C-KIT、FLT3-ITD、NPM1、CEBPACytogeneticMolecularfeatures(PML/RARα、AML1/ETO、CBFb/MYH11、MLL)2.Labfindings63DiagnosiccriteriaClinicalmanifestationPeripheralbloodchangesAnemiaThrombocytopeniaLeukemiccellsBonemarrowexaminationleukemiccells>20%64DifferentialdiagnosisMyelodysplasticsyndromes(MDS)LeukemoidreactionAplasticanemia65Jamesw,etal.Blood,2002,100(7):229266ManagementGeneralmanagement:SupportivecarestreatingofongoinginfectionsandpreventingChemotherapy,usuallycombinedremedyProphylacticandtreatmentofextramedullaryleukemiaImmunotherapyBMT67ChemotherapyGOALS:AchieveCompleteRemmission(CR);ProlongDiseaseFreeSurvival(DFS);Curethedisease68PrinciplesofChemotherapySelectionofdrugsandprotocolsDrugsfocusingondifferentcellcyclesDrugsworkingcorporatelyNoseveroverlapoftoxicity69Anti-LeukemiaDrugs:
Killers:makingtheleukemiccellsdead---mostofthedrugsweuseInducerofdifferentiation:leadingtheblaststomatureones---ATRAPromotorofApotosis:leadingleukemiccellsto“naturaldeath”---As2O370StrategyofChemotherapyTherapeuticperiodandintermittentperiodRemissionInductionTherapyPost-RemissionTherapy71TreatmentInductionConsolidationmaintenance72Treatmentstrategy73ALL:RemissionInduction
DVPRegimen:Daunomycin(D)45mg/m2/d,D1-3(15-17)orIdarubicin(ID)8-12mg/m2/d,D1-3(15-17)Vincristine(V)1.4mg/m2/d,D1,8,15,22Prednisone(P)40mg/m2/d,D1-28CRrate: adult----80~90%74NCCNGuidelineforAML75AML:Remissioninduction
DARegimen:
Daunomycin(D)60-90mg/m2/d,D1-3
orIdarubicin(ID)8-12mg/m2/d,D1-3Ara-C(A)150mg/m2
/d,D1-7HARegimen:Harringtonin(H)3-4mg/d,D1-3Ara-C(A)150mg/m2/d,D1-7CRrate:65-85%76PostremissiontherapyAccordingtocytogeneticsandmolecularabnormalitiesBetter–riskorintermediate-risk(nodonor)HD-AraC2.0g/m2,q12h,d1,d2,d3Intermediate-risk:Allo-PBSCTPoor-risk:Allo-PBCST7778Acutepromyelocyticleukemia(APL))DiagnosisBM:cellularmorphologyCytogenetics:t(15;17)Molecularfeature:PML-RAROthers:t(11;17)→PLZF—RARα,NuMA–RARαt(5;17)→NPM—RARαAML-M3a79CytogeneticsandmolecularfeaturesofAPLcytogeneticsIncidenceinAPLFusiongeneClinicalfeaturest(15;17)(q22;q21)>95%PML-RARaATRA
sensitiveRARa-PMLArsenic
sensitivet(11;17)(q23;q21)0.8%PLZF-RARaATRAnosensitiveRARa-PLZFArsenic
resistancet(11;17)(q13;q21)rareNuMA-RARaATRAsensitivet(5;17)(q35;q21)<0.5%NPM-RARaATRAsensitiveRARa-NPMder(17)rareSTAT5b-RARa?ATRA
sensitive80InductiontherapyWBC>10X109/L(highrisk)ATRA:25mg/m2/d,d1-CRIDA:8mg/m2/d,d2,4,6,8;orDNR:45-60mg/m2/d,d1-3±Ara-CATO0.16mg/kg/d,d1-CRWBC<10X109/L(lowrisk)ATRA+IDA
orDNR+ATO81ConsolidationtherapyLowriskATRA:25mg/m2/d,d1-d14IDA:8mg/m2/d,orDNR60mg/m2/dx3dHighriskATRA+IDA8mg/m2/d,orDNR60mg/m2/dx3d+Ara-C150mg/m2/dx7d.ATRA+HHT2mg/m2/dx3d+Ara-C1.0g/m2q12hx3d.(1course)2courses2courses82MaintenancetherapyLowriskATRA:20mg/m2/dx14d.(onemonths)ATO:0.16mg/kg/dx14d,interval14d,0.16mg/kg/dx14d(thesecondandthirdmonths)
5cycles83MaintenancetherapyHighriskATRA:20mg/m2/dx14d.(onemonths)ATO:0.16mg/kg/dx14d,interval14d,0.16mg/kg/dx14d(thesecondandthirdmonths)MTX15mg/m2/wx4w6-MP50mg/m2/dx28d(thefourthmonths)
5cycles84DualMechanismofAs2O385ATRAandATOcombinationProcNatlAcadSciUSA.2004;101:5328-5335.
8687APLtherapy
PrimaryAPLATRA+As2O3+ChemotherapyHCR
CTX2~3courses
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 初中语文七年级下册第六单元课外古诗词诵读《过松源晨炊漆公店(其五)》教学设计
- 小学四年级道德与法治《这些事我来做》第一课时活动化教学设计
- 九年级化学教学设计:酸碱盐核心概念建构与物质转化推理
- 高二化学选择性必修3胺与酰胺教学设计
- 小学六年级心理健康《缓解压力有办法》教学设计
- 掘金智能AI调香系统万亿蓝海:核心壁垒与闭环
- 十五五智能土壤氮磷钾传感器:边缘计算在低功耗设备中的融合
- 技术平权时代 宠物智能用品赛道 2026年广东省宠物智能用品创业计划品牌策划
- 炫酷英文企业宣传模板
- 房地产营销部销售绩效分析表
- DB45-T 2875-2024 矿山生态修复工程技术规范
- AI赋能小学语文整本书阅读实施方案
- 加气站变更管理制度(3篇)
- 《CATIA-V5R21基础与应用案例教程》(共9章)第七章钣金设计
- 手术部位感染的预防及控制措施
- 油漆店面应急预案
- 2025年四川省内江市专业技术继续教育公需科目考试及答案
- 工程合同外增加项补充协议模板
- 风电设备典型故障诊断处理指导手册第3册2025
- 2025年陕西陕煤集团榆林化学有限责任公司招聘笔试参考题库含答案解析
- 2025年国信证券股份有限公司招聘笔试参考题库含答案解析
评论
0/150
提交评论